Phantom Pharmaceuticals, Inc.
News
Zurcher Kantonalbank Zurich Cantonalbank Boosts Holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)
Ticker Report Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 42.2% during the 2nd quarter, HoldingsChannel reports. The firm...\n more…
Needham & Company LLC Reiterates "Buy" Rating for Phathom Pharmaceuticals (NASDAQ:PHAT)
Ticker Report Phathom Pharmaceuticals (NASDAQ:PHAT - Get Free Report)s stock had its "buy" rating reaffirmed by stock analysts at Needham Company LLC in a report issued on Friday, Benzinga reports...\n more…
Phathom Pharmaceuticals (NASDAQ:PHAT) Sets New 52-Week High at $17.25
Ticker Report Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $17.25 and last traded at $17.11...\n more…
Buy Rating for Phathom Pharmaceuticals Amid Strong Voquezna Prescription Growth
TipRanks Financial Blog Analyst Joseph Stringer from Needham maintained a Buy rating on Phathom Pharmaceuticals (PHAT - Research Report) and keeping the price target at $2...\n more…
Following Up On Phathom Pharmaceuticals
SeekingAlpha Following Up On Phathom Pharmaceuticals...\n more…
Phathom Pharmaceuticals (NASDAQ:PHAT) Rating Reiterated by Needham & Company LLC
Ticker Report Phathom Pharmaceuticals (NASDAQ:PHAT - Get Free Report)s stock had its "buy" rating reaffirmed by analysts at Needham Company LLC in a report issued on Friday, Benzinga reports. They...\n more…